Beyer Jana, Jäger Yvonne, Balci Derya, Kolb Gelia, Weschenfelder Friederike, Seeger Sven, Schlembach Dietmar, Abou-Dakn Michael, Schleußner Ekkehard
Klinik für Geburtsmedizin, Universitätsklinikum Jena, Jena, Germany.
Klinik für Geburtshilfe, Krankenhaus St. Elisabeth und St. Barbara Halle, Halle, Germany.
Geburtshilfe Frauenheilkd. 2022 Aug 10;82(8):868-873. doi: 10.1055/a-1860-0419. eCollection 2022 Aug.
The efficacy, safety, and perinatal outcome of oral misoprostol (OM), a misoprostol vaginal insert (MVI), and a dinoprostone vaginal insert (DVI) for induction of labor at term was examined in a prospective multicenter cohort study (ethics committee vote 4154-07/14). The primary aims of the study were the induction-birth interval (IBI), the cumulative delivery rates after 12 h, 24 h, and 48 h as well as the mode of delivery. 322 pregnant women were included in four German tertiary perinatal centers (MVI 110, DVI 64, OM 148). They did not vary in age or BMI. Statistical analysis was carried out using a multivariate linear regression analysis and binary logistic regression analysis. With regards to the median IBI, MVI and OM were equally effective and superior to the DVI (MVI 823 min [202, 5587]; DVI 1226 min [209, 4909]; OM 847 min [105, 5201]; p = 0.006). Within 24 hours, 64% were able to deliver with DVI, 85.5% with MVI and 87.5% with OM (p < 0.01). The rates of secondary Caesarean sections (MVI 24.5%; DVI 26.6%; OM 18.9%) did not differ significantly. Uterine tachysystole was found in 20% with MVI, 4.7% with DVI and 1.4% with OM (p < 0.001). A uterine rupture did not occur in any of the cases. Perinatal acidosis occurred (umbilical cord arterial pH < 7.10) in 8.3% with MVI, 4.7 with DVI and 1% with OM (p = 0.32). Neonatal condition was only impaired in three cases (5-minute Apgar score < 5). Induction of labor at term using the prostaglandins misoprostol and dinoprostone is an effective intervention that is safe for the mother and child. Oral application of misoprostol demonstrated the highest efficacy while maintaining a favorable safety profile.
在一项前瞻性多中心队列研究(伦理委员会投票4154 - 07/14)中,对口服米索前列醇(OM)、米索前列醇阴道栓剂(MVI)和地诺前列酮阴道栓剂(DVI)足月引产的疗效、安全性及围产期结局进行了研究。该研究的主要目的是引产至分娩间隔时间(IBI)、12小时、24小时和48小时后的累积分娩率以及分娩方式。322名孕妇纳入德国四个三级围产期中心(MVI组110例、DVI组64例、OM组148例)。她们在年龄或体重指数方面无差异。采用多元线性回归分析和二元逻辑回归分析进行统计分析。关于中位IBI,MVI和OM同样有效且优于DVI(MVI 823分钟[202, 5587];DVI 1226分钟[209, 4909];OM 847分钟[105, 5201];p = 0.006)。24小时内,DVI组64%能够分娩,MVI组为85.5%,OM组为87.5%(p < 0.01)。二次剖宫产率(MVI组24.5%;DVI组26.6%;OM组18.9%)无显著差异。MVI组20%出现子宫收缩过速,DVI组为4.7%,OM组为1.4%(p < 0.001)。所有病例均未发生子宫破裂。围产期酸中毒(脐动脉pH < 7.10)在MVI组为8.3%,DVI组为4.7%,OM组为1%(p = 0.32)。仅3例新生儿情况受损(5分钟阿氏评分< 5)。使用前列腺素米索前列醇和地诺前列酮进行足月引产是一种对母婴安全的有效干预措施。口服米索前列醇在保持良好安全性的同时显示出最高疗效。